SOPRANO: Macitentan in patients with pulmonary hypertension following left ventricular assist device implantation

SOPRANO: Macitentan in patients with pulmonary hypertension following left ventricular assist device implantation

Abstract Macitentan is a dual endothelin receptor antagonist (ERA) approved for treating pulmonary arterial hypertension (PAH). SOPRANO evaluated the efficacy and safety of macitentan versus placebo in pulmonary hypertension (PH) patients after left ventricular assist device (LVAD) implantation. SOP...

Full description

Bibliographic Details
Main Authors: Robert P. Frantz, Shashank S. Desai, Gregory Ewald, Veronica Franco, Antoine Hage, Evelyn M. Horn, Shane J. LaRue, Michael A. Mathier, Stacy Mandras, Myung H. Park, Ashwin K. Ravichandran, Joel D. Schilling, I‐wen Wang, Ronald Zolty, Gabriela Gomez Rendon, Mark A. Rocco, Mona Selej, Carol Zhao, J. Eduardo Rame
Format: Article
Language:English
Published: Wiley 2024-10-01
Series:Pulmonary Circulation
Subjects:
left ventricular assist device
macitentan
pulmonary hypertension
pulmonary vascular resistance
SOPRANO
Online Access:https://doi.org/10.1002/pul2.12446

Internet

https://doi.org/10.1002/pul2.12446

Similar Items